5:03 PM
 | 
May 08, 2014
 |  BC Extra  |  Company News

FDA approves Merck's Zontivity

FDA approved an NDA for Zontivity vorapaxar from Merck & Co. Inc. (NYSE:MRK) to reduce the risk of heart attack, stroke, cardiovascular death, and need for procedures to...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >